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Numerous studies now support that human immunodeﬁciency virus type 1 (HIV-1) evolution is inﬂuenced
by immune selection pressure, with population studies showing an association between speciﬁc HLA alleles and
mutations within deﬁned cytotoxic T-lymphocyte epitopes. Here we combine sequence data and functional
studies of CD8 T-cell responses to demonstrate that allele-speciﬁc immune pressures also select for mutations
ﬂanking CD8 epitopes that impair antigen processing. In persons expressing HLA-A3, we demonstrate con-
sistent selection for a mutation in a C-terminal ﬂanking residue of the normally immunodominant Gag KK9
epitope that prevents its processing and presentation, resulting in a rapid decline in the CD8 T-cell response.
This single amino acid substitution also lies within a second HLA-A3-restricted epitope, with the mutation
directly impairing recognition by CD8 T cells. Transmission of the mutation to subjects expressing HLA-A3
was shown to prevent the induction of normally immunodominant acute-phase responses to both epitopes.
However, subsequent in vivo reversion of the mutation was coincident with delayed induction of new CD8 T-cell
responses to both epitopes. These data demonstrate that mutations within the ﬂanking region of an HIV-1
epitope can impair recognition by an established CD8 T-cell response and that transmission of these mutations
alters the acute-phase CD8
 T-cell response. Moreover, reversion of these mutations in the absence of the
original immune pressure reveals the potential plasticity of immunologically selected evolutionary changes.
It is well established that human immunodeﬁciency virus
type 1 (HIV-1)-speciﬁc CD8
 T-cell responses are important
to the control of HIV-1 replication, in particular during the
acute phase of infection (3, 10, 15, 34, 40, 56). A number of
mechanisms that HIV-1 uses to evade these host immune re-
sponses have now been described, including impairment of
HIV-1-speciﬁc CD4
 and CD8
 T-cell function (8, 21), down-
regulation of HLA class I molecules (25, 57, 65), and mutations
within deﬁned cytotoxic T-lymphocyte (CTL) epitopes (3, 10,
31). The role of sequence variation within epitopes as a means
of immune escape has been well documented in infected per-
sons as well as in vaccine challenge studies, and recent studies
now support a role for CD8
 T-cell selective pressures in also
shaping the global sequence diversity of HIV-1 (44, 68). Trans-
mission of such evolving CD8 escape mutations can, therefore,
have a direct impact on the ability of newly infected individuals
to mount effective CD8
 T-cell responses against particular
HIV-1 epitopes during acute infection, as illustrated in the
case of mother-to-child transmission (32). This ﬁnding is fur-
ther supported by a recent study illustrating that individuals
expressing rare HLA alleles within a population, against which
less immune selection pressure is likely to have been applied at
the population level, may have a selective advantage in con-
taining HIV-1 replication (61).
Viral escape from CTL responses due to mutation of resi-
dues within the targeted epitope has been described for both
HIV-1 and simian immunodeﬁciency virus (3, 10, 16, 26, 30, 33,
35, 38, 45, 48, 49, 63, 64). Such mutations either directly impact
the ability of the epitope to bind and be presented on the
surface of a cell by the major histocompatibility complex
(MHC) class I molecule or alter the ability of the T-cell re-
ceptor (TCR) to properly engage and recognize the MHC-
peptide complex. Mutations within ﬂanking regions of epitopes
can also potentially inhibit CD8
 T-cell responses by interfer-
ing with the proper processing of these antigens, but this is yet
to be shown during the natural course of human viral infec-
tions. There are multiple steps required for the successful
processing of a CD8 epitope which could be sensitive to se-
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 quence variations both within and ﬂanking an epitope, includ-
ing proteasomal cleavage of endogenously synthesized proteins
(14, 47, 60, 68), transporter associated with antigen-processing
(TAP) activity (1), and aminopeptidase N-terminal trimming
(13, 29, 39, 42, 60). Although the impact of mutations ﬂanking
epitopes has been shown for experimentally induced mutations
(11, 19, 22, 24, 46), whether speciﬁc CD8
 T-cell responses
play a role in the selection of these mutations during natural
infection remains unknown (19).
Here, we study the rapidly mutating retrovirus HIV-1 and
show evolution of a single amino acid mutation distal to the C
terminus of an epitope which inhibits normal processing and
presentation of this typically immunodominant epitope. The
same mutation also lies within a second CTL epitope and leads
to impaired MHC-peptide-TCR interaction. Additional HLA-
A3-positive subjects infected with circulating strains of HIV-1
harboring mutations in this position were unable to mount
acute-phase responses against these normally immunodomi-
nant epitopes (67), demonstrating not only that transmission of
these mutations is occurring, but also that they can impair the
critical early cellular immune responses.
MATERIALS AND METHODS
Subjects. Twenty-two HIV-1-infected subjects were enrolled from the Boston
Acute Infection Cohort. Thirteen individuals expressed the HLA class I allele
A3, and an additional nine individuals were HLA-A3 negative. All study subjects
were identiﬁed during primary HIV-1 infection and were successfully treated
with highly active antiretroviral therapy, with the exception of subject AC-38,
who remained untreated. Longitudinal studies were performed on HLA-A3-
positive subjects AC-38, AC-33, and AC-14. Subject AC-38 was diagnosed with
early HIV-1 infection following high-risk exposure. An HIV-1 p24 Gag enzyme-
linked immunosorbent assay (ELISA) 49 days prior to presentation had been
negative but was positive by day 14 postpresentation. At the earliest measure-
ment on day 59, viral loads were 1,500 copies of HIV-1 RNA per ml of plasma
with a CD4
 T-cell count of 697 cells per l. HIV-1 viremia remained controlled
to levels below 2,000 copies/ml for the ﬁrst year of infection, with a rise in viral
load to 9,020 copies/ml at day 435. The subject subsequently moved and was
temporarily lost to follow-up until 3 years postinfection (day 1073), when viral
loads had risen to 60,000 copies/ml. By day 1213 and day 1510, viral loads were
slightly lower at 11,200 copies/ml and 19,700 copies/ml, respectively. Subjects
AC-33 and AC-14 were both treated during acute HIV-1 infection with viral
loads greater than 500,000 RNA copies/ml and 95,000 RNA copies/ml, respec-
tively, and underwent one or more structured treatment interruptions with peak
viral rebounds between 15,000 and 110,000 RNA copies/ml.
IFN- ELISPOT assay. HIV-1-speciﬁc CD8
 T-cell responses were quantiﬁed
by gamma interferon (IFN-) ELISPOT assay as previously described (67), using
overlapping peptides (15- to 18-mer peptides overlapping by 10 amino acids)
spanning the entire expressed HIV-1 clade B 2001 consensus sequence (http:
//hiv-web.lanl.gov), as well as peptides corresponding to optimal described clade
B CTL epitopes (18) and autologous virus sequences when available. The num-
ber of speciﬁc IFN--secreting T cells were counted by automated reader, cal-
culated by subtracting the negative control value and expressed as spot-forming
cells (SFC) per 10
6 input cells. A response was considered positive if there were
50 SFC per 10
6 cells and at least three times greater than mean background
activity. CD8
 T-cell dependence of all responses was conﬁrmed by CD4
/
CD8
 T-cell depletion-enrichment studies using magnetic beads (MACS; Milte-
nyi Biotech, Bergisch Gladbach, Germany) (67). Comparison of autologous and
variant epitopes was performed using log dilutions of peptides as described
elsewhere (6).
Flow cytometric detection of antigen-induced intracellular IFN-. Intracellu-
lar cytokine staining assays were performed as described previously (4). Cells
were analyzed on a FACSort ﬂow cytometer (Becton Dickinson Immunocytom-
etry Systems, San Jose, Calif.). Vaccinia virus experiments, utilizing constructs
vT135 and vT142 (NIH AIDS Reagent Program), were performed by infecting
BLCL target cells overnight with a multiplicity of infection of 3:1, as described
previously (4). Target cells were then washed three times and used in the assay
at an effector-to-target ratio of 10:1.
Sequencing of autologous virus. Nested PCR for p17 and p24 on proviral
DNA or plasma viral RNA was performed as previously described (6). PCR
fragments were population sequenced to identify regions of sequence variation
and where necessary were additionally cloned (TOPO TA; Invitrogen, Carlsbad,
Calif.) and DNA mini-prepped (QiaPrep Turbo mini-prep). All fragments were
sequenced bidirectionally on an ABI 3100 PRISM automated sequencer. Se-
quencher (Gene Codes Corp., Ann Arbor, Mich.) and MacVector 4.1 (Oxford
Molecular) were used to edit and align sequences.
HLA-A0301 peptide binding assays. Quantitative assays for the binding of
peptides to soluble HLA-A0301 molecules based on the inhibition of binding of
a radiolabeled standard probe peptide to HLA-A0301 molecules were per-
formed as previously described (59). Binding values were then calculated relative
to the 50% inhibitory concentration (IC50) of the standard probe peptide.
Statistical analysis. Statistical analysis and graphical presentation were done
using SigmaPlot 5.0 (SPSS Inc., Chicago, Ill.). Statistical analysis of signiﬁcance
(P values) was based on the chi-square test.
Nucleotide sequence accession numbers. Sequence data are available from
GenBank under accession numbers AY611238 through AY611385.
RESULTS
Loss of two immunodominant HLA-A3-restricted CD8
 T-
cell responses is associated with sequence variation at p17
residue K28. Previous studies have shown that HLA-A3-re-
stricted CD8
 T-cell responses directed against two overlap-
ping immunodominant epitopes in p17 Gag (KIRLRPGG
K18-26 [KK9] and RLRPGGKKK20-28 [RK9]) are frequently
involved in acute-phase responses to primary HIV-1 infection
(7, 27, 67). To determine the effects of CD8
 T-cell-mediated
immune selection pressure on subsequent viral evolution
within these epitopes, HIV-1 Gag-speciﬁc CD8
 T-cell re-
sponses in eight HLA-A3 subjects mounting both RK9- and
KK9-speciﬁc responses during acute HIV-1 infection (AC-38,
-14, -06, -01, -03, -15, -21, and -23) were studied with respect to
magnitude of CD8 T-cell response and sequence of autologous
virus within the targeted region. These subjects were followed
longitudinally by IFN- ELISPOT assay using described HIV-
1 Gag epitope peptides (18).
The ﬁrst of these subjects (AC-38), who never initiated an-
tiretroviral therapy, exhibited a CD8
 T-cell response directed
against six HIV-1 Gag CD8 epitopes at the ﬁrst available time
point 64 days following presentation with primary HIV-1 in-
fection (negative HIV-1 p24 Gag ELISA 49 days prior to pre-
sentation and indeterminant ELISA at presentation, becoming
positive at day 14). The initially immunodominant CD8
 T-cell
response was directed against the HLA-B57-restricted epitope
TW10 (TSTLQEQIGW) (Fig. 1), but this response declined
FIG. 1. Decline of HLA-A3-restricted RK9 and KK9 CD8 T-cell
responses in subject AC-38. HIV-1 Gag-speciﬁc CD8
 T-cell re-
sponses were followed longitudinally in HLA-A3-positive subject
AC-38 during untreated HIV-1 infection using the IFN- ELISPOT
assay and described optimal epitope peptides. The magnitude of these
responses is indicated in SFC per 10
6 PBMC.
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 following viral escape (TSNLQEQIGW) by as early as day 64
(data not shown). Other CD8
 T-cell responses, reaching T-
cell frequencies of 1,000 SFC/10
6 peripheral blood mononu-
clear cells (PBMC), were generated against the two overlap-
ping HLA-A3-restricted epitopes in Gag, KK9 and RK9, as
well as two other HLA-B57-restricted epitopes, IW9 (ISPRT
LNAW147-155) and KF11 (KAFSPEVIPMF162-172). Finally, a
subdominant response was directed against the HLA-A1-re-
stricted GY9 epitope (GSEELRSLY71-79). Longitudinal as-
sessment of the four immunodominant responses from early
throughout chronic infection in AC-38 revealed that while the
two immunodominant HLA-B57-restricted responses were
maintained, the two HLA-A3-restricted responses declined
(Fig. 1). In order to determine whether viral sequence evolu-
tion and immune escape could be the cause of this decline,
bulk and clonal sequencing of these A3-restricted epitopes
were undertaken in this subject. These data demonstrated that
at p17 residue K28 a lysine-to-glutamine (K28Q) substitution
appeared between day 435 and day 1073 after infection (Table
1), coincident with the decline in the KK9 and RK9 responses.
Transient sequence variations over time at two other residues
in this region (R20W and K26I) were also present prior to the
K28Q mutation (Table 2) becoming ﬁxed, but these did not
persist.
Additional longitudinal characterization of p17 RK9- and
KK9-speciﬁc CD8
 T-cell responses was performed in the
remaining seven HLA-A3 subjects in whom acute-phase re-
sponses to KK9 and RK9 were detected. These subjects were
identiﬁed and treated during acute HIV-1 infection but under-
went subsequent treatment interruptions associated with sub-
stantial viral replication (between 18,000 and 78,000 RNA cop-
ies/ml in seven of eight subjects). Of these subjects, AC-14 also
exhibited a signiﬁcant decline in both the RK9- and KK9-
speciﬁc responses associated with the development of both
K26R and K28Q mutations (4.5 years postpresentation) (Table
3). Similarly, subject AC-06, who was superinfected with a
second strain of virus (6), also experienced a decline in mag-
nitude of CD8 T-cell responses to both epitopes, even though
the only sequence change was in position K28 (K28T) within
epitope RK9, with epitope KK9 unchanged. In the remaining
ﬁve HLA-A3 subjects who demonstrated acute-phase re-
sponses to these epitopes, no signiﬁcant decline in the RK9
and KK9 responses over time was observed (range, 50 to 69
months follow-up) in the presence of ongoing viral replication
following treatment interruption (Table 3 and data not shown).
Thus, of a total of eight HLA-A3-expressing persons examined,
three experienced a loss of CD8
 T-cell responses against both
immunodominant HLA-A3-restricted p17 Gag epitopes asso-
ciated with amino acid substitutions at residue K28.
Impact of the p17 Gag K28 mutation on epitope processing
and recognition by KK9- and RK9-speciﬁc CD8
 T-cell lines.
We next examined the effects of the K28 mutation on process-
ing, presentation, and recognition of the two HLA-A3-re-
stricted epitopes. As the p17 K28 mutation is located at the
C-terminal position of the HLA-A3-restricted RK9 epitope,
we initially assessed the impact of this mutation on CD8

T-cell responses directed against this epitope by comparing the
wild-type peptide and the K28Q variant peptide for their abil-
ities to bind to HLA-A3 and be effectively recognized by RK9-
speciﬁc T-cell lines. The K28Q mutation reduced the binding of
the RK9 epitope to the HLA-A3 molecule from an IC50 of 21
nM to 162 nM and inhibited recognition by RK9-speciﬁc
CD8
 T-cell lines when target cells were directly labeled with
the variant epitope peptide (Fig. 2A). Each of the sequence
variations within the RK9 epitope that arose in subject AC-38,
shown in Table 1, was also tested using nonexpanded autolo-
gous PBMC from this individual. These variant peptides all
dramatically reduced recognition (Fig. 2B). These data suggest
that the C-terminal K28Q mutation represents an escape mu-
tation within the HLA-A3-restricted RK9 epitope impacting
peptide-MHC-TCR interactions.
The loss of responses to the KK9 epitope, in which there
were no mutations to affect peptide-TCR-MHC interactions,
suggested that processing of the KK9 epitope may have been
impaired by the K28Q mutation in the C-terminal ﬂanking
region. To address this, B cells were infected with HIV-1 p55-
expressing vaccinia virus constructs encoding either the wild-
type epitope (Vac T135; K28) or the variant epitope (Vac T142;
K28Q) (Table 2). Intracellular cytokine staining assays revealed
that while both the KK9- and RK9-speciﬁc CD8
 T-cell lines
were capable of recognizing target cells infected with the au-
tologous T135 vaccinia virus, neither line was capable of rec-
ognizing target cells infected with the T142 variant vaccinia
virus expressing the K28Q mutation (Fig. 3). A control CD8

TABLE 2. Vaccinia virus constructs
Vaccinia virus
construct
b Sequence
a
KIRLRPGGK
RLRPGGKKK
10 20 30 40
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRE
vT135 (WT) ...........K..A..............R...L.......
vT142 (K28Q) ......I....K..A............Q.RM..L.......
a For reference, sequences are aligned to the clade B consensus sequence.
b NIH AIDS Research and Reference Reagent Program.
TABLE 1. Viral evolution within the HLA-A3-restricted p17 KK9
and RK9 epitopes in subject AC-38: clonal sequencing
Days post-
presen-
tation
Clonal sequence
a Clonal fre-
quency
b
KIRLRPGGK
RLRPGGKKK
10 20 30 40
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRE
64 .............................R.......... 8/17
...................W.........R.......... 9/17
435 .............................R.......... 3/5
.........................I...R.......... 2/5
1073 ...........................Q.R.......... 6/11
...........................Q.R....I..... 5/11
1213 ...........................Q.R.......... 11/14
.............G.............Q.R.......... 3/14
a For reference, sequences were aligned to the clade B consensus sequence.
b Clonal sequences were derived from proviral DNA.
VOL. 78, 2004 ANTIGEN-PROCESSING MUTATION IN HIV INFECTION 7071
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 TABLE 3. Evolving or transmitted HIV-1 p17 K28 mutations impair mounting of HLA-A3-restricted RK9 and KK9 responses
Subject HLA Time point
(days postpresentation)
Sequence
a
KIRLRPGGK
RLRPGGKKK
ELISPOT
b Clonal
frequency
c
(%) KK9 RK9
K28 mutations are associated with
loss of KK9/RK9 responses:
AC-38 A3 Acute (64) ........... 1,470 1,310
Chronic (1213) ..........Q 220 140
AC-14 A3 Acute (26) R.......... 1,200 630
Chronic (1660) R.......R.Q 100 210
AC-06
d A3 Virus A (18) ........... 1,100 1,000
Virus B (1170) ..........T 150 120
AC-01 A3 Acute (16) ........... 130 480
AC-03 A3 Acute (30) ........... 60 250
AC-15 A3 Acute (10) ........... 440 660
AC-21 A3 Acute (4) ........... 120 800
AC-23 A3 Acute (20) ........... 0 170
Acute acquired K28 mutations impair
mounting of KK9/RK9
responses in HLA-A3 subjects
AC-05 A3 Acute (24) ........R.Q 00
AC-20 A3 Acute (8) .......S..R 00
AC-24 A3 Acute (1) .......R..Q 00
AC-33 A3 Acute (1) .......S..R 00
AC-58 A3 Acute (6) ..........Q 00
Frequency of transmission of K28
variants in non-HLA-A3
subjects
AC-02 Non-A3 Acute (27) ........R.Q ND ND
AC-09 Non-A3 Acute (1) ........... ND ND
AC-10 Non-A3 Acute (5) ........... ND ND
AC-16 Non-A3 Acute (1) ........... ND ND
AC-25 Non-A3 Acute (1) R.........Q ND ND
AC-26 Non-A3 Acute (1) ........... ND ND
AC-27 Non-A3 Acute (0) ..........Q ND ND
AC-45 Non-A3 Acute (9) ..........Q ND ND
AC-59 Non-A3 Acute (1) ........... ND ND
Reversion of a transmitted K28R
variant enables mounting of
KK9/RK9 responses
AC-33 A3 0 .......S..R 0 0 14/14 (100)
.......S... 0/14 (0)
482 .......S..R 0 0 21/24 (87)
.......S... 3/24 (13)
811 .......S..R 810 1,370 9/12 (75)
.......S... 3/12 (25)
1006 .......S..R ND ND 9/15 (60)
.......S... 6/15 (40)
1413 .......S..R 1,120 1,020 0/21 (0)
.......S... 21/21 (100)
1534 .......S..R 310 590 5/9 (56)
.......S... 4/9 (44)
a Population sequences derived from virus isolated from PBMC. For subjects AC-38 and AC-33, viral RNA was also sequenced.
b Indicates peak IFN- ELISPOT response (SFC/10
6 PBMC) against consensus KK9 and RK9. ND, not determined.
c Clones derived from virus isolated from both PBMC and plasma.
d Previously published (6).
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 T-cell line against the HLA-B14-restricted DA9 epitope
(DRFYKTLRA298-306) in p24 that was conserved within both
vaccinia virus constructs was able to efﬁciently recognize target
cells infected with either vaccinia virus. Western blot quanti-
tation of lysates from both wild-type-infected and variant vac-
cinia virus-infected cells supported proper p17 expression by
all vaccinia viruses (data not shown), ensuring that these re-
sults were not due to defective protein expression by the T142
variant vaccinia virus, but rather to impaired presentation of
the KK9 epitope to the respective T-cell lines. Taken together,
these data indicate that the K28Q mutation resulted in im-
paired processing and recognition of the KK9 epitope by epi-
tope-speciﬁc CD8
 T cells.
As proteasomes have been shown to be important in the
generation of many CD8 epitopes (11, 19, 22, 24, 46), we used
a proteasomal cleavage prediction program which models in
vivo cleavage to determine the potential of this mutation to
alter antigen processing. The proteasomal cleavage prediction
program NetChop C-term 2.0 (36) was utilized to determine
whether any of the K28 variants of p17 would be predicted to
be less effectively processed than the wild-type sequence. This
program is trained against a database of MHC class I ligands
and designed to predict cleavage sites of the human protea-
some (36, 68). This analysis revealed that the probability for
cleavage at residue 28 dropped dramatically from 59.8% for
the wild-type sequence to 1.3, 1.2, and 11.3% for the K28Q,
K28T, and K28R variants, respectively, when tested using an
HIV-1 clade B consensus p17 sequence. This program also
suggested that the only other two sequence variations between
the vaccinia virus constructs in the vicinity of the A3 epitopes,
namely, positions 7 (V7I) and 31 (L31M), would not be pre-
dicted to inﬂuence processing of the KK9 epitope (data not
shown). These data support a role for the K28Q mutation in
impairing the proper antigen processing of the KK9 epitope by
altering a proteasomal cleavage site.
Finally, analysis of a more extensive Western Australia Se-
quence database (180 sequences from HLA-deﬁned chronic
HIV-infected subjects [44]) supported the impact of immune
pressure upon this region of Gag. A strong HLA-A0301-
associated selection at residue K28 for glutamine (Q; 28%) or
arginine (R; 29%) substitutions was detected, with the overall
odds ratio for selective pressures upon this residue in HLA-
A0301 subjects versus non-A0301 subjects being 6.3 (P 
0.0001). This association remained signiﬁcant (odds ratio of
6.0; P  0.0001) after adjusting for other HLA-A, -B, -C, and
-DR alleles. Taken together, these data demonstrate that mu-
tations in Gag position K28 can impair both the recognition of
the HLA-A3-restricted RK9 epitope and the processing of the
FIG. 2. Impaired recognition of variant RK9 epitope in subject AC-38. (A) Peptide-speciﬁc responses exhibited by RK9-speciﬁc CD8
 T-cell
lines were quantiﬁed by ﬂow cytometry using intracellular IFN- staining. The wild-type peptide (RK9) was recognized by 28.1% of CD8
 T cells,
while the RQ9 variant peptide was poorly recognized (0.8%). (B) Peptide-speciﬁc responses exhibited by autologous unstimulated PBMC from
subject AC-38 were quantiﬁed by IFN- ELISPOT. Each of the variant RK9 peptides showed reduced reactivity compared to the autologous
peptide (RLRPGGKKK).
VOL. 78, 2004 ANTIGEN-PROCESSING MUTATION IN HIV INFECTION 7073
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 HLA-A3-restricted KK9 epitope, resulting in an HLA-A3
“footprint” on the sequence of HIV-1 in this position.
Transmission of HIV-1 p17 K28 variants impairs induction
of HLA-A3-restricted CD8 T-cell responses. It was previously
observed that not all individuals expressing HLA-A3 mounted
KK9- and RK9-speciﬁc CD8
 T-cell responses during acute
HIV-1 infection (67). Therefore, we were interested in assess-
ing whether infection with viruses harboring p17 K28 mutations
might explain the inability of some HLA-A3-expressing sub-
jects to mount these responses. Five additional HLA-A3 sub-
jects (AC-05, -20, -24, -33, and -58) were chosen based on their
inability to mount acute-phase KK9 or RK9 responses (Table
3). Sequencing of acute-phase autologous virus indicated that
viruses from all ﬁve subjects exhibited an amino acid substitu-
tion in position K28 (P  0.001 compared to eight individuals
mounting responses), as well as in some cases additional mu-
tations (Table 3). These data suggest that infection with the
K28 variant impairs the ability of HLA-A3-expressing individ-
uals to mount primary CD8
 T-cell responses against these
otherwise immunodominant epitopes during acute infection.
Given the relatively high allele frequency of HLA-A3
(13.2%) in U.S. Caucasians (20) and the development of this
escape mutation in persons expressing this allele, we next ex-
amined viruses obtained from HIV-1-infected persons identi-
ﬁed and treated during acute infection who did not express
HLA-A3 for the presence of this mutation. Sequence analysis
of KK9 and RK9 epitopes in these nine additional HLA-A3-
negative HIV-1-infected subjects during acute infection re-
vealed K28 mutations in four of these subjects (Table 3). Given
that these viruses were sequenced during acute infection and
before signiﬁcant immune selective pressures could develop,
these mutations are likely to have been transmitted. Together
with the population data presented above, showing a strong
association between this K28 mutation and expression of HLA-
A3, the data suggest that these persons acquired viruses ex-
posed to prior HLA-A3-speciﬁc positive selection pressures.
Reversion of the p17 K28 mutation is associated with de-
layed mounting of KK9- and RK9-speciﬁc CD8
 T-cell re-
sponses. The above data demonstrate that immune pressure
can result in escape mutations at residue K28 in p17 Gag and
FIG. 3. KK9- and RK9-speciﬁc CD8 T-cell lines fail to recognize target cells infected with vaccinia virus expressing the K28Q variant. Cell lines
were tested for recognition of target cells infected with vaccinia virus expressing either wild-type sequences of RK9 and KK9 (Vac T135) or the
K28Q variant sequence (Vac T142). KK9- and RK9-speciﬁc cell lines failed to recognize target cells infected with vaccinia virus expressing the K28Q
variant, while target cells infected with the wild-type vaccinia virus induced strong IFN- production. A control CD8
 T-cell line speciﬁc for the
HLA-B14-restricted p24 Gag epitope DRFYKTLRA (DA9) that was conserved in both vaccinia viruses (T135 and T142) recognized infected
target cells equally well. Target cells infected with the control vaccinia virus Lac were used as negative controls.
7074 ALLEN ET AL. J. VIROL.
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 that the transmission of these variant viruses to other individ-
uals expressing HLA-A3 inhibits the development of these
normally immunodominant responses in acute infection. We
next studied the genetic stability of this escape variant follow-
ing transmission. Of the ﬁve HLA-A3 individuals infected with
aK 28 mutation who lacked KK9- and RK9-speciﬁc T-cell re-
sponses, one subject (AC-33) was able to mount delayed re-
sponses to both epitopes. This individual was infected with a
strain of HIV-1 encoding two variants within this region of p17
Gag, including a K28R mutation (Table 3). The earliest detect-
able CD8
 T-cell response in this subject was directed against
the HLA-B44-restricted p24 CD8
 T-cell epitope AW11
(AEQASQDVKNW174-184; 220 SFC/10
6 PBMC), which arose
during acute HIV-1 infection prior to initiation of therapy
(data not shown). No HLA-A3-restricted responses against the
KK9 or RK9 epitopes were detectable at this time. However,
811 days postinfection (387 days after stopping therapy) both
KK9- and RK9-speciﬁc responses were detected, and these
responses became the dominant HIV-1-speciﬁc CD8
 T-cell
responses in this individual (810 and 1,370 SFC/10
6 PBMC,
respectively). While the analysis of immune responses directed
against the variant RK9 epitope (RLRPGSKKR) using autol-
ogous unstimulated PBMC from this time point conﬁrmed
impaired recognition of this transmitted variant, the reverted
“wild-type” epitope, RLRPGSKKK, was very well recognized
(Fig. 4). Sequence analysis of autologous HIV-1 demonstrated
full reversion of this K28R variant back to wild type by day 1413
(Table 3), consistent with the late appearance of these two
responses and suggesting that the switch to wild-type sequence
was due to epitope reversion in the absence of the immune
pressure that selected for this mutation. Interestingly, analysis
of virus sequences and CD8
 T-cell responses in subject
AC-33 at the latest time point available (day 1534) indicated a
partial return of the K28R variant in plasma virus (56% of
clones assessed) and a partial decline of RK9- and KK9-spe-
ciﬁc T-cell responses. These data support immune pressure
mediated by these HLA-A3-restricted responses on this epi-
tope (Table 3) and reﬂect a remarkable dynamic interplay
between immune responses and viral sequence variation.
DISCUSSION
CD8
 T-cell responses play a critical role in the containment
of HIV-1. Escape from these responses during the course of
HIV-1 infection through mutations within targeted epitopes
has been observed and may represent a signiﬁcant challenge to
long-term immune control of HIV-1 replication. Herein we
describe an additional mechanism of immune escape that
would not have been apparent from simply sequencing the
targeted epitopes. In this case, a Gag epitope that is frequently
targeted in persons expressing HLA-A3 was impacted by a
single amino acid mutation in its C-terminal ﬂanking region
which inhibited the processing and presentation of the epitope.
The same mutation also lies within a second partially overlap-
ping HLA-A3 epitope, inhibiting immune recognition of this
epitope by the well-characterized escape mechanism involving
impairment of peptide-TCR-HLA interactions. The observa-
tion that other HLA-A3 subjects infected with HIV-1 strains
encoding similar mutations were unable to mount responses
against either of these epitopes during acute infection illus-
trates not only that horizontal transmission of antigen-process-
ing mutations occurs, but also that these mutations can under-
mine the development of otherwise immunodominant CD8

T-cell responses against HIV-1.
Many factors impact the selection and immunodominance of
CD8
 T-cell responses. These include the kinetics of pathogen
protein production (37, 50, 54), proteasome speciﬁcity (14, 47,
60, 68), TAP transport (1), N-terminal trimming (13, 29, 39, 42,
60), MHC binding (52, 58), and TCR availability and afﬁnity
(12, 23, 28). A recent study by Yusim et al. supports an im-
portant role for proteasome processing sites in the selection of
CD8 epitopes in HIV-1 (68). Here, we have illustrated the
development of an antigen-processing escape mutation in
HIV-1 as a consequence of an HLA-A3-restricted virus-spe-
ciﬁc CD8
 T-cell response. Three out of the eight HLA-A3-
expressing subjects studied developed an amino acid substitu-
tion at residue K28 of p17 that was associated with the loss of
CD8
 T-cell responses against both immunodominant HLA-
A3-restricted p17 Gag epitopes. It is interesting that in subject
AC-38 the K28Q mutation ultimately evolved, despite the fact
that the transient R20W and K26I mutations effectively im-
pacted recognition by RK9-speciﬁc responses. These transient
R20W and K26I mutations were also found to strongly impact
recognition of KK9-speciﬁc responses (data not shown). These
data may suggest preferential selection for the K28 processing
mutation in the evasion from these HLA-A3-restricted CD8

T-cell responses. Alignments of the KK9 and RK9 epitopes
from the Los Alamos HIV Sequence Database (http://hiv-web
.lanl.gov) also indicate a higher degree of sequence variation at
residue K28 with the K28Q (8%), K28R (6%), and K28T (6%)
mutations occurring most frequently, and data from the West-
ern Australia Sequence database (44) analyzed here support
the impact of immune pressure upon this region of Gag in
HLA-A3-infected individuals.
Identiﬁcation of a CD8
 T-cell response as the underlying
driving force for selection of an antigen-processing mutation
has not been previously described. However, single amino acid
residue variations between different murine leukemia virus and
HIV-1 isolates in regions ﬂanking CD8 epitopes have previ-
ously been shown to alter proper epitope processing (11, 22,
24). Similarly, mutations within deﬁned CD8 epitopes between
different murine leukemia virus and HIV-1 strains have also
been shown to impact antigen processing (46, 66). Together,
these studies suggest that understanding the impact of HIV-1
FIG. 4. Impaired recognition of variant RK9 epitope in subject
AC-33. Peptide-speciﬁc responses exhibited by autologous unstimu-
lated PBMC from subject AC-33 were quantiﬁed by IFN- ELISPOT.
Each of the variant RK9 peptides showed reduced reactivity compared
to the autologous peptide (RLRPGSKKK).
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 sequence variation on recognition by CD8
 T-cell responses
will not be limited to mutations within deﬁned CD8 epitopes
and that evasion of host CD8
 T-cell responses by HIV-1
through processing mutations may be more common than pre-
viously appreciated.
Selection for CD8 epitope antigen-processing mutations
may provide a unique advantage to HIV-1 in the setting of
transmission. While transmitted mutations within an epitope
would presumably only beneﬁt the virus if the subsequent host
expressed the same restricting HLA molecule, antigen-pro-
cessing mutations that prevent proper presentation of a larger
region of HIV-1 could prove beneﬁcial regardless of the re-
cipient’s HLA molecules. Considering that some conserved
regions of gag and hydrophobic stretches of nef encode sub-
stantial numbers of clustered CD8 epitopes (5, 43, 68), im-
paired antigen processing within these regions could have a
signiﬁcant impact on the ability of the newly infected host to
mount effective CD8 responses. The impact of such mutations
may be analogous to the impact that alterations in glycosyla-
tion sites have upon evasion of numerous neutralizing antibody
responses (2, 17, 55, 62). The observation that some HLA-A3
subjects fail to mount responses against these normally immu-
nodominant HIV-1-speciﬁc CD8
 T-cell epitopes due to in-
fection with viruses containing K28 variants indicates that at
the population level transmitted mutations can impair a host’s
ability to mount immunodominant CD8
 T-cell responses. As
HLA-A3 represents a frequent HLA allele expressed within
Caucasian populations, our data illustrating transmission of an
HLA-A3-restricted CD8 escape processing mutation may pro-
vide some experimental explanation for the recent report that
individuals expressing HLA class I alleles that are frequent in
a population experience a more rapid HIV-1 disease progres-
sion (61).
The degree to which reversion of CTL escape mutations is
occurring after transmission into a new host remains unknown
but will be crucial for determining the rate by which these
mutations are accumulating within circulating HIV-1 strains.
Reversion is likely dependent upon the impact of the mutation
on viral ﬁtness or replicative capacity (9, 41, 51, 53). Transmit-
ted mutations no longer required to evade host CD8
 T-cell
responses, or which compromise the structure or function of an
HIV-1 protein, may be more likely to revert. The observed
reversion of the K28R mutation to wild-type sequence in sub-
ject AC-33 may suggest that a ﬁtness cost to the virus may be
associated with maintenance of such mutations. Therefore, a
balance between escape and reversion within HIV-1-speciﬁc
CD8 T-cell epitopes, inﬂuenced by the frequency of HLA
alleles within a population (44), may determine the overall
integrity and conservation of CD8 T-cell epitopes in the viral
population.
The observed escape from an immunodominant CD8
 T-
cell response through an antigen-processing mutation further
highlights the approaches available to HIV-1 to evade host
immune responses. As these processing mutations may repre-
sent an effective way for HIV-1 to escape from multiple host
CD8
 T-cell responses, a better understanding of the extent to
which these mutations develop, are being transmitted, and may
be reverting will be important not only to our understanding of
HIV-1 pathogenesis but also to the selection and design of
antigens capable of effectively inducing immune responses.
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